MX2020006533A - Inhibidores del receptor activado por proteasa-2. - Google Patents

Inhibidores del receptor activado por proteasa-2.

Info

Publication number
MX2020006533A
MX2020006533A MX2020006533A MX2020006533A MX2020006533A MX 2020006533 A MX2020006533 A MX 2020006533A MX 2020006533 A MX2020006533 A MX 2020006533A MX 2020006533 A MX2020006533 A MX 2020006533A MX 2020006533 A MX2020006533 A MX 2020006533A
Authority
MX
Mexico
Prior art keywords
sub
inhibitors
activated receptor
protease activated
par
Prior art date
Application number
MX2020006533A
Other languages
English (en)
Inventor
Bernard Luke Flynn
Luigi Aurelio
Nigel Bunnett
Le Giang
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017905084A external-priority patent/AU2017905084A0/en
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020006533A publication Critical patent/MX2020006533A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere generalmente a compuestos capaces de inhibir el Receptor Activado por Proteasa-2 (PAR2). y sus usos. Más específicamente. la presente invención se refiere a inhibidores de PAR2, a su preparación y a su uso en el tratamiento de enfermedades y trastornos mediados por la señalización de PAR2.
MX2020006533A 2017-12-20 2018-12-19 Inhibidores del receptor activado por proteasa-2. MX2020006533A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017905084A AU2017905084A0 (en) 2017-12-20 Inhibitors of Protease Activated Receptor-2
PCT/JP2018/047988 WO2019124567A1 (en) 2017-12-20 2018-12-19 Inhibitors of protease activated receptor-2

Publications (1)

Publication Number Publication Date
MX2020006533A true MX2020006533A (es) 2020-12-09

Family

ID=65244543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006533A MX2020006533A (es) 2017-12-20 2018-12-19 Inhibidores del receptor activado por proteasa-2.

Country Status (10)

Country Link
US (1) US20200383985A1 (es)
EP (1) EP3727386A1 (es)
JP (1) JP2021508692A (es)
CN (1) CN111698991A (es)
AU (1) AU2018388104A1 (es)
BR (1) BR112020012589A2 (es)
CA (1) CA3086458A1 (es)
EA (1) EA202091524A1 (es)
MX (1) MX2020006533A (es)
WO (1) WO2019124567A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197463A1 (en) * 2016-05-20 2017-11-23 Monash University Treatment of pain
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4896870B2 (ja) * 2004-04-08 2012-03-14 ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
EP2119455A1 (en) 2004-04-08 2009-11-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tripartite raftophilic structures and their use
HK1223096A1 (zh) * 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
WO2017197463A1 (en) * 2016-05-20 2017-11-23 Monash University Treatment of pain

Also Published As

Publication number Publication date
JP2021508692A (ja) 2021-03-11
EA202091524A1 (ru) 2020-09-16
CN111698991A (zh) 2020-09-22
AU2018388104A1 (en) 2020-07-09
EP3727386A1 (en) 2020-10-28
CA3086458A1 (en) 2019-06-27
WO2019124567A1 (en) 2019-06-27
BR112020012589A2 (pt) 2020-11-24
US20200383985A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
ZA202502749B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
MX2018010374A (es) Inhibidores del enlace proteína-proteína de wdr5.
MX2018006223A (es) Moduladores de ror-gamma.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
TN2016000238A1 (en) Tricyclic compounds as anticancer agents.
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
HK1257296A1 (zh) 新的化合物及其用途
MX2022011564A (es) Tratamiento del dolor.
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX2020006533A (es) Inhibidores del receptor activado por proteasa-2.
EA202191115A1 (ru) Новые пиридазины
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
WO2019040104A3 (en) COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
GB2553685A (en) Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis